IMPemBra


Protocolnummer:
NL54421.031.15

Ziekenhuizen:
NKI / A.v.L ziekenhuis Amsterdam

Titel:
Phase 2 Study Comparing Pembrolizumab with Intermittent/Short-term Dual MAPK Pathway Inhibition Plus Pembrolizumab in patients harboring the BRAFV600 mutation (IMPemBra) Het doel van het onderzoek: To explore the safety, feasibility, and the immune-activating capacity of different schemes of continuous/intermittent dabrafenib+trametinib during treatment with pembrolizumab as compared to pembrolizumab monotherapy

Behandeling:
Pembrolizumab mono en in 3 schema’s gecombineerd met dabrafenib+trametinib

Stadium:
Stadium irresectable IIIc/IV

Belangrijkste in/exclusiecriteria:

stage IV BRAF V600E or K positive metastatic melanoma, ECOG PS 0-2, no prior immunotherapy or BRAF and MEK targeting therapy, excl brain metastases, autoimmune disease

Contactpersoon:
Christian Blank (internist-oncoloog)

Alle trials